CMS To Kick Off Year Of Potentially Major Drug Pricing Developments With National Coverage Policy For Aduhelm

By John Wilkerson / January 10, 2022 at 5:00 PM
The year ahead will include legislation, lawsuits and administrative actions that could impact pharmaceutical drug prices, and while much could happen in the next 12 months, this might be the week with one of the most important developments on drug pricing in 2022. Wednesday (Jan. 12) is the deadline for Medicare’s draft national coverage policy for the pricy drug Aduhelm and other monoclonal antibody amyloid treatments for Alzheimer’s that are in the pipeline; the final decision is due in April...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.